Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Robert D. Bunning"'
From Hip to Heart: A Comprehensive Evaluation of an Infiltrative CardiomyopathyNovel Teaching Points
Autor:
Manavotam Singh, MD, Mrinalini Krishnan, MD, Amre Ghazzal, MD, Marc Halushka, MD, James E. Tozzi, MD, Robert D. Bunning, MD, Maria E. Rodrigo, MD, Samer S. Najjar, MD, Ezequiel J. Molina, MD, Farooq H. Sheikh, MD
Publikováno v:
CJC Open, Vol 3, Iss 11, Pp 1392-1395 (2021)
Infiltrative cardiomyopathies are an increasingly recognized cause of heart failure warranting systematic evaluation. Given overlap of clinical and imaging findings among etiologies of infiltrative cardiomyopathies, comprehensive evaluation, includin
Externí odkaz:
https://doaj.org/article/b144048ac77d45d68bbc1da77ba3c691
Autor:
Ezequiel J. Molina, Farooq H. Sheikh, Robert D. Bunning, James E. Tozzi, Mrinalini Krishnan, Samer S. Najjar, Marc K. Halushka, Maria E. Rodrigo, Manavotam Singh, Amre Ghazzal
Publikováno v:
CJC Open
Infiltrative cardiomyopathies are an increasingly recognized cause of heart failure warranting systematic evaluation. Given overlap of clinical and imaging findings among etiologies of infiltrative cardiomyopathies, comprehensive evaluation, includin
Publikováno v:
PM&R. 7:447-450
This report describes 2 cases of metallosis from metal-on-polyethylene total hip replacements. Case 1 involved a Stryker rejuvenate implant, which has since been recalled. This patient had minimal symptoms, an elevated cobalt level, and loosening. Th
Publikováno v:
PM&R. 8
Autor:
Robert D. Bunning, Michael J. Auriemma
Publikováno v:
PM&R. 8
Publikováno v:
PMR : the journal of injury, function, and rehabilitation. 9(4)
Lead toxicity in adults is characterized by nonspecific symptoms of abdominal pain, vomiting, constipation, fatigue, and weight loss. We present a case of severe lead toxicity that developed subacutely, causing quadriparesis 9 years after a gunshot w
Publikováno v:
PM&R. 10:S73-S73
Publikováno v:
PM&R. 10:S17-S17
Publikováno v:
PM&R. 2:76-80
Bisphosphonate therapy for the treatment of postmenopausal osteoporosis is common, with more than 22 million prescriptions for alendronate (Merck) alone in 2005. The safety of this class of medications has been supported by long-term trials [1,2]. Ho
Autor:
Cyrus Kao, Robert D. Bunning
Publikováno v:
PM&R. 6